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Table 1. Characteristics of lymphatic filariasis prevalence studies where microfilaraemia (pMF) and antigenemia (pICT) were 
assessed in the same sample population  
 









median (IQR) median (IQR) 
Africa aBenin MoH, 20021 Benin 0/1 519 0.4  519 0  
aBurkina Faso MoH, 20102 Burkina Faso 6/3 3478 7.4 (2.3-8.7) 2520 18.8 (10.1-20.7) 
aCote d’Ivoire, 20093 Cote d'Ivoire 3/0 794 1.9 (1.2-2.5) 230 16.9 (1.2-17.3) 
Ramzy et al., 19994 Egypt 0/4 1813 2.9 (1.9-6.6) 1813 8.2 (4.4-12.7) 
Ramzy et al., 20065 Egypt 10/2 9127 1.3 (0.3-2.9) 11134 5 (3-12.1) 
Geshere et al., 20126 Ethiopia 0/1 123 0  60 0  
aGhana MoH, 20017 Ghana 0/9 915 20 (18-23) 915 40 (37-42) 
Simonsen et al., 20028 Kenya 0/1 1013 2.7  1013 16.5  
Njenga et al., 20119 Kenya 8/8 2498 10.6 (1-22.2) 2505 21.6 (10.5-33.9) 
Nielsen et al., 200210 Malawi 0/2 537 21.5 (20.3-22.6) 507 64.4 (63.4-65.4) 
aNiger MoH, 200810 Niger 0/2 984 0.9 (0.4-1.4) 150 21.5 (17-26) 
aNiger MoH, 200911 Niger 2/0 1075 0.3 (0.2-0.4) 150 34.5 (17-52) 
aNigeria MoH, 200412 Nigeria 7/2 2726 1.8 (1.7-7.4) 2726 15.3 (1.8-22.9) 
aNigeria MoH, 200613 Nigeria 9/0 1163 0.7 (0.5-2.5) 1163 0.7 (0.5-2.5) 
aNigeria MoH, 200814 Nigeria 10/0 1013 0 (0-2.7) 1013 7.4 (1.8-9.8) 
aNigeria MoH, 200915 Nigeria 3/0 1472 1.8 (1.2-3.1) 0 0 
aNigeria MoH, 201016 Nigeria 0/3 1294 10.8 (2.9-12.3) 50 0 (0-46) 
Richards et al., 201117 Nigeria 34/10 9897 1.1 (0-3.9) 9332 10.1 (5.5-22.3) 
Ekanem et al., 201118 Nigeria 0/1 222 0 222 17.1  
Ebenezer et al., 201119 Nigeria 0/1 1803 7  1803 11.3  
aTogo MoH, 200120 Togo 0/7 3500 1.2 (0.8-10.6) 615 4.9 (2.7-31.3) 
aTogo MoH, 200821 Togo 3/0 1501 0 (0-2) 1785 2.6 (0.3-8.4) 
Meyrowitsch et al., 200422 Tanzania 2/0 1024 18.4 (16.7-20.1) 1024 44.3 (43.5-45.1) 
Onapa et al., 2001b23 Uganda 0/1 173 0  289 0  
Onapa et al., 2001a24 Uganda 0/3 1257 22.4 (9.7-25.5) 2686 29.1 (18.3-30.1) 
aUganda MoH, 201025 Uganda 4/0 2062 0.2 (0-0.5) 454 0  
Ashton et al., 201126 Uganda 14/0 938 4.7 (0-8.7) 1398 13 (3.4-37.5) 









median (IQR) median (IQR) 
Americas Aguiar-Santos et al., 201327 Brazil 0/1 159 1.2  159 13.8  
Braga et al., 200328 Brazil 0/1 625 6.8  625 31.7  
Braga et al., 200529 Brazil 0/1 1130 6.9  790 25.7  
De Rochars et al., 200530 Haiti 0/4 455 9.5 (7.4-13.5) 455 35.7 (22.4-43.5) 
Boyd et al., 201031 Haiti 6/0 3499 4.4 (4.2-7.4) 3465 16.9 (11.8-28.7) 
Asia Ramaiah et al., 2007b32 India 0/1 238 17.2  57 17.5  
Chhotray et al., 200533 India 0/2 4297 10.3 (9.5-11) 2400 17.3 (16.8-17.8) 
Sunish et al., 200134 India 0/1 3505 12.2  3505 23.7  
Ramaiah & Vanamail, 201335 India 3/0 415 0.4 (0-3.6) 415 3.6 (0-4) 
Chandrasena et al., 200236 Sri Lanka 0/2 226 30.8 (27.5-34.2) 226 34.8 (34.2-35.3) 
Gunawardena et al., 200737 Sri Lanka 24/0 4008 0  4008 1.4 (0-3.7) 
Bhumiratana et al., 199938 Thailand 0/1 225 5.8 225 20  
Bhumiratana et al., 200239 Thailand 0/1 219 3.7  219 23.7  
Oceania bWHO Country report Fiji 4/0 6762 0.7 (0.2-1.6) 6762 7 (1.9-13.3) 
WHO Annual report, 200340 New Caledonia 0/1 382 3.6  382 32.5  
Fraser et al., 200541 Vanuatu 10/8 2079 2.2 (0-7.1) 2079 10.2 (3.9-27.2) 
Ichimori et al., 200742 Samoa 1/0 4054 1.1  4054 4.2  
Joseph et al., 201143 Samoa 7/0 1269 0.5 (0.2-0.6) 1269 14.6 (8.4-16.7) 
cWHO Country report Samoa 7/0 6448 0.4 (0.2-0.8) 6448 2.1 (0.7-3) 
 
ICT: immuno-chromatographic test; mf: microfilariae; IQR = inter-quartile range. 
 





1. Benin MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; BEN0004_LF2002.Cotonou: Benin Ministry of Health; 2002. 
2. Burkina Faso MoH. Programme to Eliminate Lymphatic Filariasis. Country 
Report WHO; BFA0020_LF2010. Ouagadougou: Burkina Faso Ministry of Health; 
2010. 
3. Cote d’Ivoire MoH; Programme to Eliminate Lymphatic Filariasis. Country 
Report WHO; CIV0003_LF2009. Abidjan: Cote d'Ivoire Ministry of Health; 2009. 
4. Ramzy RM, Helmy H, el-Lethy AS et al. Field evaluation of a rapid-format kit 
for the diagnosis of bancroftian filariasis in Egypt. East Mediterr Health J 1999;5:880-
7. 
5. Ramzy RM, El Setouhy M, Helmy H et al. Effect of yearly mass drug 
administration with diethylcarbamazine and albendazole on bancroftian filariasis in 
Egypt: a comprehensive assessment. Lancet 2006;367:992-9.  
6. Geshere Oli G, Tekola Ayele F, Petros B. Parasitological, serological and 
clinical evidence for high prevalence of podoconiosis (non-filarial elephantiasis) in 
Midakegn district, central Ethiopia. Trop Med Int Health 2012;17:722-6.  
7. Ghana MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO;GHA0020_LF2001. Accra: Ghana Ministry of Health; 2001. 
8. Simonsen PE, Meyrowitsch DW, Jaoko WG et al. Bancroftian filariasis 
infection, disease, and specific antibody response patterns in a high and a low 
endemicity community in East Africa. Am J Trop Med Hyg 2002;66:550-9. 
9. Njenga SM, Mwandawiro CS, Wamae CN et al. Sustained reduction in 
prevalence of lymphatic filariasis infection in spite of missed rounds of mass drug 
administration in an area under mosquito nets for malaria control. Parasit Vectors 
2011;4:90.  
10. Nielsen NO, Makaula P, Nyakuipa D et al. Lymphatic filariasis in Lower Shire, 
southern Malawi. Trans R Soc Trop Med Hyg 2002;96:133-8. 
11. Nigeria MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; NER0009_LF2009. Abuja: Niger Ministry of Health; 2009. 
12. Nigeria MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; NGA0004_LF2004. Abuja: Nigeria Ministry of Health; 2004. 
13. Nigeria MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; NGA0007_LF2006. Abuja: Nigeria Ministry of Health; 2006. 
14. Nigeria MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; NGA0013_LF2008. Abuja: Nigeria Ministry of Health; 2008. 
15. Nigeria MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; NGA0014_LF2009. Abuja: Nigeria Ministry of Health; 2009. 
16. Nigeria MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; NGA0016_LF2010. Abuja: Nigeria Ministry of Health; 2010. 
17. Richards FO, Eigege A, Miri ES et al. Epidemiological and entomological 
evaluations after six years or more of mass drug administration for lymphatic 
filariasis elimination in Nigeria. PLoS Negl Trop Dis 2011;5:e1346.  
18. Ekanem IA, Alaribe AAA, Ekanem AP. Prevalence of Bancroftian Filariasis 
among Edim Otop sub-urban dwellers in Calabar Municipality of Cross River state, 
Nigeria. J Appl Pharm Sci 2011;01. 
19. Ebenezer A, Amadi EC, Agi PI. Studies on the microfilaria, antigenemia and 
clinical signs of bancroftian filariasis in Epie creek communities, Niger Delta, Nigeria. 
Int Res J Microbiol 2011;2:370–4. 
20. Togo MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; TGO0003_LF2001. Lome: Togo Ministry of Health; 2001. 
21. Togo MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; TGO0015_LF2008. Lome: Togo Ministry of Health; 2008. 
22. Meyrowitsch DW, Simonsen PE, Magesa SM. A 26-year follow-up of 
bancroftian filariasis in two communities in north-eastern Tanzania. Ann Trop Med 
Parasitol 2004;98:155-69.  
23. Onapa AW, Simonsen PE, Pedersen EM. Non-filarial elephantiasis in the Mt. 
Elgon area (Kapchorwa District) of Uganda. Acta Trop 2001;78:171-6. 
24. Onapa AW, Simonsen PE, Pedersen EM et al. Lymphatic filariasis in Uganda: 
baseline investigations in Lira, Soroti and Katakwi districts. Trans R Soc Trop Med 
Hyg 2001;95:161-7. 
25. Uganda MoH. Programme to Eliminate Lymphatic Filariasis. Country Report 
WHO; UGA0014_LF2010. Kampala: Uganda Ministry of Health; 2010. 
26. Ashton RA, Kyabayinze DJ, Opio T et al. The impact of mass drug 
administration and long-lasting insecticidal net distribution on Wuchereria bancrofti 
infection in humans and mosquitoes: an observational study in northern Uganda. 
Parasit Vectors 2011;4:134.  
27. Aguiar-Santos AM, Medeiros Z, Bonfim C et al. Epidemiological assessment 
of neglected diseases in children: lymphatic filariasis and soil-transmitted 
helminthiasis. J Pediatr (Rio J) 2013;89:250-5. 
28. Braga C, Dourado MI, Ximenes RA et al. Field evaluation of the whole blood 
immunochromatographic test for rapid bancroftian filariasis diagnosis in the 
northeast of Brazil. Rev Inst Med Trop Sao Paulo 2003;45:125-9.  
29. Braga C, Dourado I, Ximenes R et al. Bancroftian filariasis in an endemic area 
of Brazil: differences between genders during puberty. Rev Soc Bras Med Trop 
2005;38:224-8.  
30. de Rochars MB, Kanjilal S, Direny AN et al. The Leogane, Haiti demonstration 
project: decreased microfilaremia and program costs after three years of mass drug 
administration. Am J Trop Med Hyg 2005;73:888-94.  
31. Boyd A, Won KY, McClintock SK et al. A community-based study of factors 
associated with continuing transmission of lymphatic filariasis in Leogane, Haiti. 
PLoS Negl Trop Dis 2010;4:e640.  
32. Ramaiah KD, Vanamail P, Das PK. Changes in Wuchereria bancrofti infection 
in a highly endemic community following 10 rounds of mass administration of 
diethylcarbamazine. Trans R Soc Trop Med Hyg 2007;101:250-5.  
33. Chhotray GP, Ranjit MR, Khuntia HK et al. Precontrol observations on 
lymphatic filariasis & geo-helminthiases in two coastal districts of rural Orrisa. Indian 
J Med Res 2005;122:388-94. 
34. Sunish IP, Rajendran R, Satyanarayana K et al. Immunochromatographic test 
(ICT) for estimation of true prevalence of bancroftian filariasis in an endemic area in 
southern India. Trans R Soc Trop Med Hyg 2001;95:607-9. 
35. Ramaiah KD, Vanamail P. Surveillance of lymphatic filariasis after stopping 
ten years of mass drug administration in rural communities in south India. Trans R 
Soc Trop Med Hyg;107:293-300.  
36. Chandrasena TGAN, Premaratnal R. Evaluation of the ICT whole-blood 
Wuchereria bancrofii in Sri Lanka card test to detect infection due to. Trans R Soc 
Trop Med Hyg 2002;96:60-3. 
37. Gunawardena GSa, Ismail MM, Bradley MH et al. Impact of the 2004 mass 
drug administration for the control of lymphatic filariasis, in urban and rural areas of 
the Western province of Sri Lanka. Ann Trop Med Parasitol 2007;101:335-41.  
38. Bhumiratana A, Koyadun S, Suvannadabba S et al. Field trial of the ICT 
filariasis for diagnosis of Wuchereria bancrofti infections in an endemic population of 
Thailand. Southeast Asian J Trop Med Public Health 1999;30:562-8. 
39. Bhumiratana A, Wattanakull B, Koyadun S et al. Relationship between male 
hydrocele and infection prevalences in clustered communities with uncertain 
transmission of Wuchereria bancrofti on the Thailand-Myanmar border. Southeast 
Asian J Trop Med Public Health 2002;33:7-17. 
40. WHO. Global Programme to Eliminate Lymphatic Filariasis. Annual Report on 
Lymphatic Filariasis 2003. Geneva: World Health Organization; 2005. 
41. Fraser M, Taleo G, Taleo F et al. Evaluation of the program to eliminate 
lymphatic filariasis in Vanuatu following two years of mass drug administration 
implementation: results and methodologic approach. Am J Trop Med Hyg 
2005;73:753-8. 
42. Ichimori K, Tupuimalagi-Toelupe P, Toeaso Iosia V et al. Wuchereria bancrofti 
filariasis control in Samoa before PacELF (Pacific Programme to Eliminate 
Lymphatic Filariasis). Trop Med Health 2007;35:261-9. 
43. Joseph H, Maiava F, Naseri T et al. Epidemiological assessment of continuing 











Sensitivity analysis upon regression model  
 
We conducted a sensitivity analysis by fitting various models based solely on thick 
smears based on 1. 20 µl of blood volume; 2. 20 to 60 µl of blood (equivalent to 1-3 
thick smears); and 3. 50 µl or 60 µl of blood, as follows:  
 
for each survey 𝑖 = 1, … , 𝑁, 
𝑌𝑚𝑓𝑖|𝑝𝑚𝑓𝑖 ∼ 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑁𝑚𝑓𝑖 , 𝑝𝑚𝑓𝑖) 
 
Model 1. Only thick smears based on 20 µl of blood 
logit (𝑝𝑀𝑓𝑖) =  𝛼 + 𝛼1logit (𝑝𝐼𝐶𝑇𝑖) + 𝛼PRE × 𝑃𝑅𝐸𝑖 + 𝛼1𝑃𝑅𝐸  logit (𝑝𝐼𝐶𝑇𝑖) × 𝑃𝑅𝐸𝑖  
 
DIC = 863.9; DIC with random effects = 316.7 
 
Model 2. Thick smears based on 20-60 µl of blood 
logit (𝑝𝑀𝑓𝑖) =  𝛼 + 𝛼1logit (𝑝𝐼𝐶𝑇𝑖) + 𝛼PRE × 𝑃𝑅𝐸𝑖 + 𝛼1𝑃𝑅𝐸  logit (𝑝𝐼𝐶𝑇𝑖) × 𝑃𝑅𝐸𝑖  
 
DIC = 2147.6; DIC with random effects = 858.3 
 
Model 3. Thick smears based on 20-60 µl of blood, and adjusting by blood 
volume 
logit (𝑝𝑀𝑓𝑖) =  𝛼 + 𝛼1logit (𝑝𝐼𝐶𝑇𝑖) + 𝛼PRE × 𝑃𝑅𝐸𝑖 + 𝛼1𝑃𝑅𝐸  logit (𝑝𝐼𝐶𝑇𝑖) × 𝑃𝑅𝐸𝑖 + 
𝛼BLOOD50 × BLOOD50 + 𝛼BLOOD60 × BLOOD60 
 
DIC = 2041.8; DIC with random effects = 852.5 
 
None of the new models improve the overall model fit and therefore we have not 
altered the results. 
